Insider Selling: Keros Therapeutics (NASDAQ:KROS) Director Sells $28,166.25 in Stock

Keros Therapeutics, Inc. (NASDAQ:KROS) Director Julius Knowles sold 2,625 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $10.73, for a total transaction of $28,166.25. Following the completion of the sale, the director directly owned 10,958 shares of the company’s stock, valued at $117,579.34. This represents a 19.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Keros Therapeutics Stock Down 1.4%

KROS stock opened at $9.93 on Thursday. The company has a market capitalization of $196.51 million, a price-to-earnings ratio of -3.30 and a beta of 0.94. Keros Therapeutics, Inc. has a 12 month low of $9.79 and a 12 month high of $22.55. The firm has a 50 day moving average of $11.28 and a two-hundred day moving average of $15.00.

Keros Therapeutics (NASDAQ:KROS) last posted its earnings results on Thursday, May 14th. The company reported ($1.21) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.19). The business had revenue of $0.37 million during the quarter, compared to the consensus estimate of $1.93 million. Keros Therapeutics had a negative return on equity of 17.04% and a negative net margin of 256.60%. On average, research analysts expect that Keros Therapeutics, Inc. will post -5.19 EPS for the current fiscal year.

Analyst Ratings Changes

KROS has been the subject of several recent research reports. Wall Street Zen downgraded shares of Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 16th. Wells Fargo & Company reduced their price objective on shares of Keros Therapeutics from $23.00 to $20.00 and set an “overweight” rating for the company in a research note on Thursday, March 5th. Finally, Weiss Ratings cut shares of Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, May 15th. Three research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $20.40.

Institutional Trading of Keros Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. ADAR1 Capital Management LLC lifted its stake in shares of Keros Therapeutics by 416.2% in the first quarter. ADAR1 Capital Management LLC now owns 97,318 shares of the company’s stock worth $1,074,000 after buying an additional 78,467 shares during the last quarter. Empowered Funds LLC lifted its stake in shares of Keros Therapeutics by 142.2% in the first quarter. Empowered Funds LLC now owns 145,517 shares of the company’s stock worth $1,607,000 after buying an additional 85,439 shares during the last quarter. Quantinno Capital Management LP raised its stake in Keros Therapeutics by 12.5% during the 1st quarter. Quantinno Capital Management LP now owns 23,759 shares of the company’s stock valued at $262,000 after purchasing an additional 2,639 shares during the last quarter. Lazard Asset Management LLC acquired a new position in Keros Therapeutics during the 1st quarter valued at $129,000. Finally, Globeflex Capital L P acquired a new position in Keros Therapeutics during the 1st quarter valued at $418,000. 71.56% of the stock is currently owned by institutional investors and hedge funds.

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-?) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.